v3.26.1
Pay vs Performance Disclosure - USD ($)
 1 Months Ended 11 Months Ended 12 Months Ended
Jan. 23, 2023
Dec. 31, 2023
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Pay vs Performance Disclosure              
Pay vs Performance Disclosure, Table    
Value of Initial Fixed $100
Investment Based On:
Year(1)
(a)
Summary
Compensation
Table Total for
Former PEO(2)
(b)
Compensation
Actually Paid to
Former PEO(3)
(c)
Summary
Compensation
Table Total for
Current PEO(2A)
(d)
Compensation
Actually Paid to
Current PEO(3A)
(e)
Average
Summary
Compensation
Table Total for
Non-PEO
NEOs(4)
(f)
Average
Compensation
Actually Paid to
Non-PEO
NEOs(5)
(g)
Total
Shareholder
Return(6)
(h)
Peer Group
Total
Shareholder
Return(7)
(i)
Net Income
(Loss) (in
thousands)(8)
(j)
Revenue (in
thousands)(9)
(h)
2025$—$—$8,856,015$6,310,790$2,699,657$2,020,841$6.03$84.57$440,302$1,123,479
2024$—$—$5,087,461$7,106,840$1,543,545$2,097,066$7.21$60.09$(187,499)$682,162
2023$3,827,483$144,984$7,269,509$3,775,263$1,712,674$1,290,595$4.30$59.25$(545,062)$983,705
2022$8,401,283$(36,557,042)$—$—$3,337,772$(11,909,621)$9.22$50.34$(657,939)$1,981,872
2021$1,118,030$43,604,574$—$—$1,546,408$10,871,879$128.30$69.59$(1,743,751)$1,146,290
        
Company Selected Measure Name     •Revenue        
Named Executive Officers, Footnote     Mr. Stanley C. Erck served as our former President and Chief Executive Officer, during 2021, 2022 and 2023, until he retired from such position on January 23, 2023. Mr. John C. Jacobs has served as our President and Chief Executive Officer since January 23, 2023. The Other NEOs reflected in columns (f) and (g) above represent the following individuals for each of the years shown:
2025 – James Kelly, Elaine O'Hara, Ruxandra Draghia-Akli M.D., John Trizzino, and Mark Casey
2024 – James Kelly, Elaine O'Hara, Filip Dubovsky M.D., John Trizzino, and Mark Casey
2023 – James Kelly, Filip Dubovsky M.D., John Trizzino, and Mark Casey
2022 – James Kelly, John Trizzino, Gregory Glenn, and John Herrmann III
2021 – James Kelly, Gregory Covino, John Trizzino, Gregory Glenn, and John Herrmann III
        
Peer Group Issuers, Footnote     Represents the weighted cumulative total return on $100 invested as of the last day of public trading in fiscal year 2020 through the last day of public trading in the applicable fiscal year for which the cumulative total return is reported, weighted according to the respective companies’ stock market capitalization at the beginning of each period for which a return is indicated. The peer group used for this purpose is the Russell 2000 Growth Biotechnology Subsector Index for all four fiscal years disclosed, which is the same peer group used in our Annual Report on Form 10-K for each of these years for purposes of Item 201(e) of Regulation S-K. The return of this index is calculated assuming reinvestment of dividends during the period presented.        
PEO Total Compensation Amount     $ 8,856,015        
PEO Actually Paid Compensation Amount     $ 6,310,790        
Adjustment To PEO Compensation, Footnote     The dollar amounts reported in column (c) and column (e) represent the amount of “compensation actually paid” to Mr. Erck and Mr. Jacobs, respectively, as computed in accordance with Item 402(v) of Regulation S-K. The dollar amounts reported in column (g) represent the average amount of “compensation actually paid” to the Other NEOs as a group, as computed in accordance with Item 402(v) of Regulation S-K. The dollar amounts do not reflect the actual amount of compensation earned by or paid to our current PEO, our former PEO, or the Other NEOs during the applicable year. In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to our PEOs’ and the Other NEOs’ total compensation for each year to determine the compensation actually paid for 2025:
2025
Current PEONon-PEO NEOs
Summary Compensation Table Total$8,856,015$2,699,657
Adjustments
Deduction for amounts reported under the “Stock Awards” and “Option Awards” columns of the Summary Compensation Table(a)
$(7,308,727)$(1,709,079)
Year End Fair Value of Equity Awards Granted in the Year$5,805,314$1,265,630
Change in Fair Value of Outstanding and Unvested Equity Awards based on Change in Fair Value from Prior Year End to Applicable Year End $(982,072)$(173,632)
Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Applicable Year based on Change in Fair Value from Prior Year End to Vesting Date $(59,740)$(61,735)
Fair Value at Vesting of Equity Awards Granted and Vested in the Fiscal Year$—$—
Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the Year$—$—
Total Equity Award Adjustments$(2,545,225)$(678,816)
Compensation Actually Paid$6,310,790$2,020,841
(a)Compensation Actually Paid excludes the amounts reported in the Stock Awards and Option Awards columns from the relevant fiscal year’s Summary Compensation Table. 		       
Non-PEO NEO Average Total Compensation Amount     $ 2,699,657 $ 1,543,545 $ 1,712,674 $ 3,337,772 $ 1,546,408
Non-PEO NEO Average Compensation Actually Paid Amount     $ 2,020,841 2,097,066 1,290,595 (11,909,621) 10,871,879
Adjustment to Non-PEO NEO Compensation Footnote     The dollar amounts reported in column (c) and column (e) represent the amount of “compensation actually paid” to Mr. Erck and Mr. Jacobs, respectively, as computed in accordance with Item 402(v) of Regulation S-K. The dollar amounts reported in column (g) represent the average amount of “compensation actually paid” to the Other NEOs as a group, as computed in accordance with Item 402(v) of Regulation S-K. The dollar amounts do not reflect the actual amount of compensation earned by or paid to our current PEO, our former PEO, or the Other NEOs during the applicable year. In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to our PEOs’ and the Other NEOs’ total compensation for each year to determine the compensation actually paid for 2025:
2025
Current PEONon-PEO NEOs
Summary Compensation Table Total$8,856,015$2,699,657
Adjustments
Deduction for amounts reported under the “Stock Awards” and “Option Awards” columns of the Summary Compensation Table(a)
$(7,308,727)$(1,709,079)
Year End Fair Value of Equity Awards Granted in the Year$5,805,314$1,265,630
Change in Fair Value of Outstanding and Unvested Equity Awards based on Change in Fair Value from Prior Year End to Applicable Year End $(982,072)$(173,632)
Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Applicable Year based on Change in Fair Value from Prior Year End to Vesting Date $(59,740)$(61,735)
Fair Value at Vesting of Equity Awards Granted and Vested in the Fiscal Year$—$—
Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the Year$—$—
Total Equity Award Adjustments$(2,545,225)$(678,816)
Compensation Actually Paid$6,310,790$2,020,841
(a)Compensation Actually Paid excludes the amounts reported in the Stock Awards and Option Awards columns from the relevant fiscal year’s Summary Compensation Table. 		       
Compensation Actually Paid vs. Total Shareholder Return     TSR: Compensation Actually Paid and Cumulative TSR
The following chart compares compensation actually paid to (i) the cumulative total return on $100 invested as of the end of fiscal year 2020 in the Company’s Common Stock and (ii) the weighted cumulative total return on $100 invested as of the end of fiscal year 2020 for the Russell 2000 Growth Biotechnology Subsector Index, in each case, for the five most recently completed fiscal years:
6192
        
Compensation Actually Paid vs. Net Income     Net Income: Compensation Actually Paid and Net Income (Loss)
The following chart compares compensation actually paid to our net income (loss) during the five most recently completed fiscal years:
6391
        
Compensation Actually Paid vs. Company Selected Measure     Compensation Actually Paid and Company Selected Measure – Revenue
The following chart compares compensation actually paid to our revenue during the five most recently completed fiscal years:
6586
        
Total Shareholder Return Vs Peer Group     TSR: Company versus Peer Group
The following chart compares (i) the cumulative total return on $100 invested as of the end of fiscal year 2020 in the Company’s Common Stock and (ii) the weighted cumulative total return on $100 invested as of the end of fiscal year 2020 for the Russell 2000 Growth Biotechnology Subsector Index, in each case, for the five most recently completed fiscal years:
5746
        
Tabular List, Table    
The performance measures listed below represent the most important financial performance measures used by the Company to link compensation actually paid to the current PEO and the Other NEOs in 2025 to the Company’s performance:
•Revenue (our CSM)
•Relative TSR (the Company’s TSR as compared to a peer group)
•Net income
        
Total Shareholder Return Amount     $ 6.03 7.21 4.30 9.22 128.30
Peer Group Total Shareholder Return Amount     84.57 60.09 59.25 50.34 69.59
Net Income (Loss)     $ 440,302,000 $ (187,499,000) $ (545,062,000) $ (657,939,000) $ (1,743,751,000)
Company Selected Measure Amount     1,123,479,000 682,162,000 983,705,000 1,981,872,000 1,146,290,000
PEO Name Stanley C. Erck John C. Jacobs John C. Jacobs John C. Jacobs   Stanley C. Erck Stanley C. Erck
Additional 402(v) Disclosure     The dollar amounts reported in column (b) and column (d) are the amounts of total compensation reported for Mr. Erck and Mr. Jacobs, respectively, for each corresponding year in the “Total” column of the Summary Compensation Table. The dollar amounts reported in column (f) represent the average of the amounts reported for the Company’s Other NEOs as a group in the “Total” column of the Summary Compensation Table in each applicable year. Refer to “Executive Compensation – Executive Compensation Tables – Summary Compensation Table.”
For the values of equity awards included in the above table, fair values are calculated in accordance with FASB ASC Topic 718. which, in the case of performance-based awards, are based on the probable outcome of the performance conditions as of the applicable measuring date or actual performance results approved by the Compensation Committee as of the applicable vesting date. Otherwise, the valuation assumptions used to calculate fair values did not materially differ from those used in our disclosures of fair value as of the grant.
Represents the cumulative total return on $100 invested in the Company’s Common Stock as of the last day of public trading of the Company’s Common Stock in fiscal year 2020 through the last day of public trading of the Company’s Common Stock in the applicable fiscal year for which the cumulative total return is reported. The Company did not pay dividends for any of 2025, 2024, 2023, 2022, or 2021.The dollar amounts reported represent the amount of net income (loss) reflected in our Annual Report on Form 10-K for the applicable year.The dollar amounts reported represent the amount of revenue reflected in our Annual Report on Form 10-K for the applicable year. We have identified revenue as our company selected measure (“CSM”) as we believe it represents the most important financial performance measure used to link compensation actually paid to our NEOs to Company performance. 		       
Measure:: 1              
Pay vs Performance Disclosure              
Name     •Revenue        
Measure:: 2              
Pay vs Performance Disclosure              
Name     Relative TSR        
Measure:: 3              
Pay vs Performance Disclosure              
Name     Net income        
John C. Jacobs [Member]              
Pay vs Performance Disclosure              
PEO Total Compensation Amount     $ 8,856,015 $ 5,087,461 $ 7,269,509    
PEO Actually Paid Compensation Amount     6,310,790 $ 7,106,840 3,775,263    
Stanley C. Erck [Member]              
Pay vs Performance Disclosure              
PEO Total Compensation Amount         3,827,483 $ 8,401,283 $ 1,118,030
PEO Actually Paid Compensation Amount         $ 144,984 $ (36,557,042) $ 43,604,574
PEO              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     (2,545,225)        
PEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     (7,308,727)        
PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     5,805,314        
PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     (982,072)        
PEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     0        
PEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     (59,740)        
PEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     0        
Non-PEO NEO              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     (678,816)        
Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     (1,709,079)        
Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     1,265,630        
Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     (173,632)        
Non-PEO NEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     0        
Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     (61,735)        
Non-PEO NEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year              
Pay vs Performance Disclosure              
Adjustment to Compensation, Amount     $ 0